ArticleAmerican journal of translational research2025
Efficacy, safety, and effect on platelet activation of the timing of administration of tirofiban in patients with acute ischemic stroke.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy, safety, and effects on platelet activation of tirofiban administered at different times in patients with acute ischemic stroke, with the goal of providing precise guidance for clinical treatment timing.
methodsA total of 262 patients with acute ischemic stroke admitted to No. 215 Hospital of Shaanxi Nuclear Industry between January 2021 and June 2023 were retrospectively analyzed. Patients were divided into an early treatment group (ETG, n = 124) and a late treatment group (LTG, n = 138) based on the timing of tirofiban administration. The ETG received tirofiban within 6 hours after thrombolysis, while the LTG received it 6 to 24 hours after thrombolysis. Clinical efficacy was evaluated post-treatment, and adverse reactions during treatment were recorded. Comparisons were made for pre- and post-treatment National Institutes of Health Stroke Scale (NIHSS) scores, Modified Rankin Scale (mRS) scores, neurological function markers, coagulation factors, inflammatory markers, and homocysteine (Hcy) levels. Correlations between efficacy and post-treatment indicators were analyzed, and logistic regression identified factors influencing outcome.
resultsThe ETG demonstrated significantly better overall efficacy than the LTG (P = 0.004). Post-treatment NIHSS and mRS scores, neuron-specific enolase (NSE), platelet-activating factor (PAF), high-sensitivity C-reactive protein (hs-CRP), Hcy, and interleukin-1β (IL-1β) levels were significantly lower in the ETG, while brain-derived neurotrophic factor (BDNF) levels were higher (all P < 0.001). Clinical efficacy correlated significantly with post-treatment mRS scores, PAF levels, and Hcy levels (all P < 0.001). The ETG also had significantly lower rates of re-occlusion (P = 0.001), cardiopulmonary complications (P = 0.004), and symptomatic cerebral hemorrhage (P = 0.035). Logistic regression showed that the LTG was associated with reduced efficacy (β = -4.469, P = 0.019), while higher post-treatment PAF (β = 2.437, P < 0.001) and Hcy levels (β = 1.782, P = 0.013) were linked to poorer outcome.
conclusionEarly administration of tirofiban in acute ischemic stroke offers significant clinical benefits, including improved neurological function and enhanced daily living abilities, with reduced inflammatory response and complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.